Sofosbuvir plus ribavirin combination regimen boost liver functions and antioxidant profile in hepatitis C virus patients.
Microb Pathog 2021;
150:104740. [PMID:
33460748 DOI:
10.1016/j.micpath.2021.104740]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 01/01/2021] [Accepted: 01/10/2021] [Indexed: 01/03/2023]
Abstract
Hepatitis C virus is an infectious pathogen affecting thousands of people causing great damage to the liver and consider an important cause of morbidity and mortality in developing countries. This research was conducted on 30 patients infected with hepatitis C virus and 10 control normal volunteers after taking consent of them in order to evaluate the liver function and antioxidants profile after treatment with combination of Sofosbuvir and Ribaverin in hepatitis C virus patients. The results showed significant reduction of elevated levels of L-Malondialdhyde, Alanine Aminotrasferase, Aspartate Aminotrasferase, Alkaline Phosphatase, Albumin, Total protein, Total bilirubin and α-fetoprotein mean while significant increase in glutathione peroxidase, catalase, superoxide dismutase activity upon treatment with combination of sofosbuvir plus ribavirin. In conclusion, the present finding suggest that, treatment of hepatitis C virus patient with combination of Sofosbuvir and Ribavirin significantly improve liver function parameters and antioxidant profile.
Collapse